| Cat. No. |
Product Name |
CAS No. |
Information |
| H9306 |
Retagliptin phosphate
|
1256756-88-3 |
Retagliptin phosphate (SP2086 phosphate) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin phosphate can be used for type 2 diabetes mellitus (T2DM) research. |
| H9305 |
Retagliptin
|
1174122-54-3 |
Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research. |
| H5093 |
Talabostat mesylate
|
150080-09-4 |
Talabostat (PT-100, Val-boroPro) is a potent, nonselective, orally available inhibitor of post-proline cleaving serine proteases with Ki of 0.18 nM for DPP4, also potently inhibits DPP8/9 (IC50=1.5/0.76 nM), FAP, DPP2 and some other DASH family enzymes; induces powerful anti-tumor immune responses in syngeneic cancer models; the inhibition of the highly related cytosolic serine proteases Dpp8 and Dpp9 (Dpp8/9) by Val-boroPro was recently demonstrated to trigger an immunostimulatory form of programmed cell death known as pyroptosis selectively in monocytes and macrophages; activates the inflammasome sensor protein Nlrp1b, which in turn activates pro-caspase-1 to mediate pyroptosis. |
| H5092 |
Talabostat
|
149682-77-9 |
Talabostat (PT-100, Val-boroPro) is a potent, nonselective, orally available inhibitor of post-proline cleaving serine proteases with Ki of 0.18 nM for DPP4, also potently inhibits DPP8/9 (IC50=1.5/0.76 nM), FAP, DPP2 and some other DASH family enzymes; induces powerful anti-tumor immune responses in syngeneic cancer models; the inhibition of the highly related cytosolic serine proteases Dpp8 and Dpp9 (Dpp8/9) by Val-boroPro was recently demonstrated to trigger an immunostimulatory form of programmed cell death known as pyroptosis selectively in monocytes and macrophages; activates the inflammasome sensor protein Nlrp1b, which in turn activates pro-caspase-1 to mediate pyroptosis.
|
| H5091 |
TAK-100
|
907609-33-0 |
TAK-100 is a potent, selective and orally active inhibitor of DPP-4 with IC50 of 5.3 nM, shows no inhibition on DPP2/8/9. |
| H5090 |
SP-13786
|
1448440-52-5 |
A highly potent, selective, orally bioavailable inhibitor of fibroblast activation protein (FAP) with IC50 of 3.2 nM, displays high selectivity against the related DPPs: DPPIV, DPP9, DPPII, and PREP (IC50=1.8 uM); demonstrates high oral bioavailability, plasma half-life, and the potential to selectively and completely inhibit FAP in vivo. |
| H5089 |
Saxagliptin hydrate
|
945667-22-1 |
A highly potent, long-acting, orally active DPP4 inhibitor with Ki of 0.6 nM; shows no CYP3A4 inhibition up to 100 uM, and good oral exposure. |
| H5088 |
Saxagliptin
|
361442-04-8 |
A highly potent, long-acting, orally active DPP4 inhibitor with Ki of 0.6 nM; shows no CYP3A4 inhibition up to 100 uM, and good oral exposure. |
| H5087 |
Omarigliptin
|
1226781-44-7 |
A potent and selective DPP-4 inhibitor with IC50 of 1.4 nM; shows high selectivity against QPP, DPP8,FAP (IC50>20 uM); efficacious in the diabetes PD model and excellent pharmacokinetic profile. |
| H5086 |
Linagliptin
|
668270-12-0 |
A highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor with IC50 of 1 nM; no significant inhibition on hERG and muscarinic receptor M1 at 1 uM; shows considerable blood glucose lowering in different animal species. |
$ USD
Select Your Country or Region